Dong-A Makes Deal For Darbepoetin Alfa With Turkey’s Polifarma
Biosimilar Version Of Aranesp/Nesp Licensed For Turkey, Brazil And Mexico
Korean developer Dong-A has signed an exclusive licensing deal with Turkey’s Polifarma covering its darbepoetin biosimilar version of Aranesp/Nesp in Turkey, Brazil and Mexico.
You may also be interested in...
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
Japan’s first biosimilar teriparatide has been approved for Mochida Pharmaceutical, while competition in the darbepoetin alfa arena looks set to step up following two recent authorizations.
Amgen has confirmed its long-awaited launch of Amjevita, the first US biosimilar rival to Humira, kicking off a year of competition that will also see a second wave of adalimumab products launch in six months’ time. The company has announced that it will offer the product at a 55% discount to the originator.